SIEMENS Healthineers

SNMMI 2022

Scientific sessions of interest

siemens-healthineers.com/mi

Saturday, June 11, 2022

Time (EDT)	Session and Title	Location	Abstract # and Title
3:15 p.m.-4:45 p.m.	SS01. Center for Therapy Excellence YIA Symposium	205/206	**2205.** Time-savings analysis of total tumor burden quantification on ^{68}Ga-PSMA-11 PET/CT with deep learning auto-segmentation of organs for automatic physiological uptake removal in men with metastatic castration-resistant prostate cancer (mCRPC)
3:15 p.m.-3:30 p.m.	SS04. Novel applications of myocardial blood flow: Informing diagnosis and prognosis in CAD	118/119/120	**2460.** Automated motion correction improves the reliability of myocardial blood flow quantification with rubidium-82 PET imaging
4:30 p.m.-4:45 p.m.	SS04. Novel applications of myocardial blood flow: Informing diagnosis and prognosis in CAD	118/119/120	**2465.** Prognostic significance of simultaneous analysis with global myocardial flow reserve and myocardial strain under vasodilator stress using cardiac PETMR
3:27 p.m.-3:20 p.m.	SS03. Physics, Instrumentation & Data Sciences YIA Symposium	118/119/120	**2515.** Towards Quantitative CT-less Total-body PET Scan
2:12 p.m.-2:24 p.m.	Integrated Session 1. Total Body PET systems: Latest Developments	205/206	**2599.** Activity optimization and evaluation of semi-quantitative performance for Biograph Vision Quadra™ PET/CT
2:48 p.m.-3:00 p.m.	Integrated Session 1. Total Body PET systems: Latest Developments	205/206	**2602.** Attenuation correction of Total Body PET using synthetic CT derived from the emission data.
3:15 p.m.-4:45 p.m.	SS01. Center for Therapy Excellence YIA Symposium	205/206	**2201.** Restoration of radioiodine uptake in Radioiodine-Refractory thyroid cancer by MAPK/BRAF Inhibition: The Single-Center Prospective Two-Arm ERRITI Trial
3:15 p.m.-4:45 p.m.	SS01. Center for Therapy Excellence YIA Symposium	205/206	**2202.** Clinical experience with ^{225}Ac-PSMA-617 TAT provided on an individual patient basis: a retrospective single-center multi-ethnics analysis of 233 patients

Saturday, June 11, 2022 (continued)

Time (EDT)	Session and Title	Location	Abstract # and Title
6:00 p.m.-8:00 p.m.	Posters - Neurosciences - Clinical Neurosciences	Exhibit Hall A	**2925.** Multivariable model for diagnosis of neurodegenerative diseases using I-123 Ioflupane incorporating machine learning
6:00 p.m.-8:00 p.m.	Posters - PIDS - Data Analysis and Management	Exhibit Hall A	**3185.** Feasibility of standard and generalized Patlak models for dynamic imaging of multiple organs using the uEXPLORER PET scanner
6:00 p.m.-8:00 p.m.	Posters - PIDS - Data Analysis and Management	Exhibit Hall A	**3192.** Shortened whole body dynamic PET ^{18}F-FDG Patlak imaging using a population input function and the Biograph Vision Quadra PET/CT
6:00 p.m.-8:00 p.m.	Posters - PIDS - Data Science	Exhibit Hall A	**3220.** Mapping FDG tracer kinetics and their uncertainties via the bootstrap using data from a Long-Axial FOV PET/CT Scanner
6:00 p.m.-8:00 p.m.	Posters - PIDS - Image Generation	Exhibit Hall A	**3252.** Data-driven gated (DDG) CT: An automated respiratory gating method to enable DDG PET/CT
6:00 p.m.-8:00 p.m.	Posters - PIDS - Image Generation	Exhibit Hall A	**3295.** Phantom-based Y-90 whole-body PET image quality evaluation
6:00 p.m.-8:00 p.m.	Posters - PIDS - Instrumentation	Exhibit Hall A	**3307.** EARL compliance of Biograph Vision Quadra PET/CT
6:00 p.m.-8:00 p.m.	Posters - Molecular Targeting Probes-Radioactive & Nonradioactive - Dosimetry & Image Analysis	Exhibit Hall A	**2811.** Serial whole-body ^{177}Lu-SPECT quantitation for response assessment in metastatic, castration-resistant prostate cancer within a phase 1/2 trial of ^{177}Lu-PSMA-617 plus NOX66 (LuPIN)
6:00 p.m.-8:00 p.m.	Posters - Molecular Targeting Probes-Radioactive & Nonradioactive - Dosimetry & Image Analysis	Exhibit Hall A	**2820.** Accurate dosimetry with fewer scans: Evaluation of the prior-information approach to ^{177}Lu-DOTATATE dosimetry
6:00 p.m.-8:00 p.m.	Poster - Educational Exhibits - General Clinical Specialties	Exhibit Hall A	**2662.** Application of Lung perfusion only scan combined with SPECT/CT for the post-treatment evaluation of massive and sub-massive pulmonary embolism in the age of Covid-19 pandemic: case presentation and literature review
6:00 p.m.-8:00 p.m.	Poster - Educational Exhibits - Correlative Imaging (including instrumentation, image fusion and data analysis)	Exhibit Hall A	**2724.** Pitfalls in the development of artificial intelligence algorithms in nuclear medicine and how to avoid them

Saturday, June 11, 2022 (continued)

Time (EDT)	Session and Title	Location	Abstract # and Title
6:00 p.m.-8:00 p.m.	Poster - Educational Exhibits - Correlative Imaging (including instrumentation, image fusion and data analysis)	Exhibit Hall A	**2725.** Best practices for evaluation of artificial intelligence-based algorithms for nuclear medicine: The RELIANCE guidelines
6:00 p.m.-8:00 p.m.	Poster - Educational Exhibits - Correlative Imaging (including instrumentation, image fusion and data analysis)	Exhibit Hall A	**2729.** Comparative assessment of attention-based deep learning and non-local mean filtering for joint noise reduction and partial volume correction in low-dose PET imaging
6:00 p.m.-8:00 p.m.	Poster - Educational Exhibits - Correlative Imaging (including instrumentation, image fusion and data analysis)	Exhibit Hall A	**2733.** Artificial intelligence ecosystem in nuclear medicine: Opportunities, Challenges, and Responsibilities
6:00 p.m.-8:00 p.m.	Poster - Education Exhibits - Professional Development & Quality Improvement	Exhibit Hall A	**2751.** Ethical risks in the development and deployment of artificial intelligence systems in nuclear medicine
6:00 p.m.-8:00 p.m.	Poster - General Clinical Specialties - Pulmonary	Exhibit Hall A	**2792.** Lung perfusion quantification using a SPECT/CT-based semi-automated segmentation workflow rather than planar perfusion scintigraphy
6:00 p.m.-8:00 p.m.	Posters - Neurosciences - Clinical Neurosciences (including neuro-oncology)	Exhibit Hall A	**2923.** Predicting cognitive decline due to Alzheimer's disease in MCI subjects by FDG-PET using assisted visual analysis
6:00 p.m.-8:00 p.m.	Posters - Neurosciences - Clinical Neurosciences (including neuro-oncology)	Exhibit Hall A	**2940.** Autoimmune encephalitis: Is FDG PET the key to diagnosis?
6:00 p.m.-8:00 p.m.	Posters - Oncology: Clinical Therapy & Diagnosis (includes Phase 2, Phase 3, post approval studies) - Endocrine/ Neuroendocrine Cancers	Exhibit Hall A	**2989.** FDG PET as a prognostic biomarker for unresectable PPGL treated with I-131 MIBG radiotherapy
6:00 p.m.-8:00 p.m.	Posters - Oncology: Clinical Therapy & Diagnosis (includes Phase 2, Phase 3, post approval studies) - Endocrine/ Neuroendocrine Cancers	Exhibit Hall A	**3004.** Utility of ^{68}Ga-DOTANOC PET/CT in culprit lesion localisation in rare entity like Tumor Induced Osteomalacia

Saturday, June 11, 2022 (continued)

Time (EDT)	Session and Title	Location	Abstract # and Title
6:00 p.m.-8:00 p.m.	Posters - Oncology: Clinical Therapy & Diagnosis (includes Phase 2, Phase 3, post approval studies) - Endocrine/ Neuroendocrine Cancers	Exhibit Hall A	**3005.** Cushing's syndrome: Role of ^{68}Ga-DOTANOC PET/CT in detection of culprit lesion
6:00 p.m.-8:00 p.m.	Posters - Oncology: Clinical Therapy & Diagnosis (includes Phase 2, Phase 3, post approval studies) - GI	Exhibit Hall A	**3038.** Impact of Y-90 glass microspheres residue measurement post-TARE using PET/CT on the tumor absorbed dose in comparison to planned dosimetry with ^{99m}Tc-MAA scintigraphy
6:00 p.m.-8:00 p.m.	Posters - Oncology: Clinical Therapy & Diagnosis (includes Phase 2, Phase 3, post approval studies) - GU	Exhibit Hall A	**3046.** Baseline imaging derived predictive factors of response following ^{177}Lu-PSMA-617 therapy in salvage metastatic castration-resistant prostate cancer; a lesion- and patient-based analysis
6:00 p.m.-8:00 p.m.	Posters - Oncology: Clinical Therapy & Diagnosis (includes Phase 2, Phase 3, post approval studies) - GU	Exhibit Hall A	**3051.** Variations of SUV_{max} and functional tumor volume on ^{18}F-PSMA1007 PET/CT scanned at different time-points and using different segmentation methods
6:00 p.m.-8:00 p.m.	Posters - Oncology: Clinical Therapy & Diagnosis (includes Phase 2, Phase 3, post approval studies) - GU	Exhibit Hall A	**3054.** Lessons learned from real life clinical experience of using ^{68}Ga-PSMA-11 for BCR at low psa levels – IUH experience in over 1000 pts.
6:00 p.m.-8:00 p.m.	Posters - Oncology: Clinical Therapy & Diagnosis (includes Phase 2, Phase 3, post approval studies) - Hematologic Malignancies	Exhibit Hall A	**3123.** Stratification of Hodgkin lymphoma patients using metabolic tumor burden and tumor dissemination calculated from baseline ^{18}FDG-PET/CT imaging
6:00 p.m.-8:00 p.m.	Posters - Oncology: Clinical Therapy & Diagnosis (includes Phase 2, Phase 3, post approval studies) - Other Solid Tumors	Exhibit Hall A	**3149.** Role of ^{18}F-FDG PET/CT in the metastatic workup of angiosarcoma
6:00 p.m.-8:00 p.m.	Posters - PIDS - Data Analysis and Management	Exhibit Hall A	**3166.** Effect of harmonization and oversampling methods on multi-center imbalanced PET datasets: Application to radiomics-based NSCLC-subtype prediction
6:00 p.m.-8:00 p.m.	Posters - PIDS - Data Analysis and Management	Exhibit Hall A	**3172.** Evaluation of the prognostic value of tumor fragmentation on [18F]-FDG PET/CT on an independent cohort of diffuse large B-cell lymphoma patients (3172)

Saturday, June 11, 2022 (continued)

Time (EDT)	Session and Title	Location	Abstract # and Title
6:00 p.m.-8:00 p.m.	Posters - PIDS - Data Analysis and Management	Exhibit Hall A	**3176.** Centiloid harmonisation across PET cameras without using paired data
6:00 p.m.-8:00 p.m.	Posters - PIDS - Data Analysis and Management	Exhibit Hall A	**3183.** Evaluation of population-based input functions for kinetic modeling of ^{18}F-FDG datasets from a long axial FOV PET scanner
6:00 p.m.-8:00 p.m.	Posters - PIDS - Data Analysis and Management	Exhibit Hall A	**3190.** Impact of Fit Time Interval on Patlak Quantitation in Dynamic Total-Body Imaging using the uEXPLORER PET Scanner
6:00 p.m.-8:00 p.m.	Posters - PIDS - Data Analysis and Management	Exhibit Hall A	**3195.** Assessment and optimization of CT radiation dose for body PET/CT across different scanner systems and different anatomical ranges
6:00 p.m.-8:00 p.m.	Posters - PIDS - Data Analysis and Management	Exhibit Hall A	**3202.** Automated liver reference region localization in PET/CT in presence of non-physiological tracer uptake
6:00 p.m.-8:00 p.m.	Posters - PIDS - Data Analysis and Management	Exhibit Hall A	**3210.** Patient-specific brain phantom SPECT database of cerebral perfusion analyzed with the 3D-data analysis platform Scenium
6:00 p.m.-8:00 p.m.	Posters - PIDS - Data Science	Exhibit Hall A	**3217.** PET as fast as CT: Ultra-fast PET imaging through a combination of digital PET/CT and post-reconstruction by artificial intelligence
6:00 p.m.-8:00 p.m.	Posters - PIDS - Data Science	Exhibit Hall A	**3246.** Dynamic FDG-PET shortened acquisition protocols determined using machine learning
6:00 p.m.-8:00 p.m.	Posters - PIDS - Data Science	Exhibit Hall A	**3250.** Multitask learning-to-rank neural network for predicting survival of diffuse large B-cell lymphoma patients from their unsegmented baseline ^{18}F-FDG-PET/CT scans
6:00 p.m.-8:00 p.m.	Posters - PIDS - Image Generation	Exhibit Hall A	**3251.** Quantitative imaging of Pb-212
6:00 p.m.-8:00 p.m.	Posters - PIDS - Image Generation	Exhibit Hall A	**3253.** Practice of domain knowledge in trustworthy deep learning for CT-free PET imaging
6:00 p.m.-8:00 p.m.	Posters - PIDS - Image Generation	Exhibit Hall A	**3255.** Variability in quantification between SPECT/CT scanners with a low-count quantitative SPECT method for alpha-particle radiopharmaceutical therapies
6:00 p.m.-8:00 p.m.	Posters - PIDS - Image Generation	Exhibit Hall A	**3271.** Maximum Likelihood Scatter and Prompt-Gamma Corrections for Myocardial Blood Flow Imaging using ^{82}Rb PET

Saturday, June 11, 2022 (continued)

Time (EDT)	Session and Title	Location	Abstract # and Title
6:00 p.m.-8:00 p.m.	Posters - PIDS - Image Generation	Exhibit Hall A	**3272.** Direct Joint Attenuation and Scatter Correction of 68-Ga-PSMA PET Images Using Deep Neural Network: A Dual-Scanner Study
6:00 p.m.-8:00 p.m.	Posters - PIDS - Image Generation	Exhibit Hall A	**3273.** Quantitative evaluation of ^{90}Y Bremsstrahlung SPECT image quality in the presence of ^{99m}Tc
6:00 p.m.-8:00 p.m.	Posters - PIDS - Image Generation	Exhibit Hall A	**3275.** Positron Range Correction Improves Rubidium-82 PET Myocardial Perfusion Image Quality
6:00 p.m.-8:00 p.m.	Posters - PIDS - Instrumentation	Exhibit Hall A	**3308.** Platform development of easily customizable brain phantoms using 3D-printing workflow
6:00 p.m.-8:00 p.m.	Posters - PIDS - Instrumentation	Exhibit Hall A	**3310.** NeuroVision: Initial Investigation into a Novel Brain PET Imaging Scanner
6:00 p.m.-8:00 p.m.	Posters - PIDS - Instrumentation	Exhibit Hall A	**3313.** Effect of ^{68}Ga radiotracer on NEMA NU-2 2018 PET-CT performance for Biograph Horizon™ scanner
6:00 p.m.-8:00 p.m.	Posters - PIDS - Instrumentation	Exhibit Hall A	**3315.** A systematic evaluation of potential clinical impact of improved image quality from a long axial field of view PET/CT
6:00 p.m.-8:00 p.m.	Posters - PIDS - Instrumentation	Exhibit Hall A	**3319.** A virtual-pinhole PET device for enhancing contrast recovery and improving lesion detectability of a one-meter-long PET scanner
	could not locate	Exhibit Hall A	**3329.** Application of list-mode based retrospective gating in patients with and without arrhythmia for myocardial perfusion SPECT
6:00 p.m.-8:00 p.m.	Poster - Cardiovascular - Clinical Science	Exhibit Hall A	**3356.** Quantitative analysis of SPECT lung ventilation/perfusion imaging in the efficacy evaluation of balloon pulmonary angioplasty in the treatment of chronic thromboembolic pulmonary hypertension
6:00 p.m.-8:00 p.m.	Poster - Cardiovascular - Clinical Science	Exhibit Hall A	**3361.** Reproducibility of ^{99m}Tc-pyrophosphate SPECT/CT cardiac amyloidosis quantitation
6:00 p.m.-8:00 p.m.	Poster - Cardiovascular - Clinical Science	Exhibit Hall A	**3363.** Usefulness of FDG-PET/CT for diagnosis of myocardial rejection after heart transplantation
6:00 p.m.-8:00 p.m.	Poster - Cardiovascular - Clinical Science	Exhibit Hall A	**3366.** The effect of semi-quantitative and quantitative analysis of SPECT V/Q scan on the efficacy of pulmonary endarterectomy in treatment of CTEPH and predicting postoperative residual pulmonary hypertension

Saturday, June 11, 2022 (continued)

Time (EDT)	Session and Title	Location	Abstract # and Title
6:00 p.m.-8:00 p.m.	Poster - Cardiovascular - Clinical Science	Exhibit Hall A	**3371.** Absolute quantitation of cardiac ^{123}I-MIBG sympathetic nerve imaging using SPECT/CT
6:00 p.m.-8:00 p.m.	Poster - Cardiovascular - Clinical Science	Exhibit Hall A	**3374.** xSPECT-based myocardial perfusion scintigraphy: feasibility of myocardial uptake quantitation in patients with suspected coronary artery disease — a pilot study
6:00 p.m.-8:00 p.m.	Poster - Cardiovascular - Clinical Science	Exhibit Hall A	**3376.** Simultaneous assessment of myocardial mechanical dyssynchrony using integrated PETMR system — Direct comparison of PET phase analysis and MR feature tracking
6:00 p.m.-8:00 p.m.	Poster - Oncology, Basic & Translational - Technical Advances & Quantification (this would include image-guided diagnostics/therapy	Exhibit Hall A	**4001.** Preliminary analysis of reproducibility of [^{68}Ga]DOTATATE PET/CT imaging of neuroendocrine tumours (NETS)
6:00 p.m.-8:00 p.m.	Poster - Oncology, Basic & Translational - Technical Advances & Quantification (this would include image-guided diagnostics/therapy	Exhibit Hall A	**4006.** "Snake" Reference Region for Aortic Input Function Extraction from Dynamic PET Data
6:00 p.m.-8:00 p.m.	Technologists Posters	Exhibit Hall A	**4116.** Image characteristics of brain perfusion SPECT/CT using a new multi-focal collimator: Comparison with conventional SPECT with LEHR collimator
6:00 p.m.-8:00 p.m.	Posters - Molecular Targeting Probes-Radioactive & Nonradioactive - Dosimetry & Image Analysis	Exhibit Hall A	**2812.** Precision in dosimetric analysis and generation of a benchmark dosimetry dataset - An IAEA study
6:00 p.m.-8:00 p.m.	Posters - PIDS - Data Science	Exhibit Hall A	**3223.** 2.5D Nouveau VAE model for ^{11}C-DASB PET image denoising and uncertainty estimation
6:00 p.m.-8:00 p.m.	Posters - PIDS - Data Science	Exhibit Hall A	**3231.** Generative Adversarial Network-Based Method for Generating DMSA Kidney SPECT Attenuation Maps from Scatter Data
6:00 p.m.-8:00 p.m.	Posters - PIDS - Image Generation	Exhibit Hall A	**3280.** Tl-208 2.6 MeV emission is the major contributor to the energy spectra when imaging Ra-224 and Pb-212
6:00 p.m.-8:00 p.m.	Posters - PIDS - Image Generation	Exhibit Hall A	**3289.** Evaluation of Novel Methods for Motion Correction in Simultaneous PET/MR

Saturday, June 11, 2022 (continued)

Time (EDT)	Session and Title	Location	Abstract # and Title
6:00 p.m.-8:00 p.m.	Posters - PIDS - Image Generation	Exhibit Hall A	**3293.** Reconstruction Parameter Assessment for Small Animal Imaging on a Clinical SiPM PET/CT
6:00 p.m.-8:00 p.m.	Poster - Cardiovascular - Clinical Science	Exhibit Hall A	**3384.** Prognostic value of global myocardial flow reserve derived from ^{99m}Tc-sestamibi dynamic SPECT in patients with intermediate coronary stenosis
6:00 p.m.-8:00 p.m.	Poster - Cardiovascular - Clinical Science	Exhibit Hall A	**3395.** Incidental extracardiac 82-rubidium uptake in myocardial perfusion PET-CT in a veteran population
6:00 p.m.-8:00 p.m.	Poster - Oncology, Basic & Translational - Technical Advances & Quantification (this would include image-guided diagnostics/therapy	Exhibit Hall A	**4007.** Dual-Energy CT Bone-Fraction Correction for Total-Body PET Kinetic Quantification of Bone Marrow
6:00 p.m.-8:00 p.m.	Poster - Oncology, Basic & Translational - In vitro and In vivo Oncology	Exhibit Hall A	**4047.** Whole-tumor MRI radiomics capture treatment response in orthotopic organoid-based patient-derived mouse model of endometrial cancer
6:00 p.m.-8:00 p.m.	Poster - General Clinical Specialties - Infectious and Inflammatory Disease/Hematology/Musculoskeletal	Exhibit Hall A	**2770.** Role of 18-F-FDG PET/CT for extent of disease and response assessment to anti fungal treatment in patients of Histoplasmosis.
6:00 p.m.-8:00 p.m.	Poster - Oncology, Basic & Translational - Early Phase Human Studies	Exhibit Hall A	**2531.** A novel SSTR antagonist ^{68}Ga-DATA5m-LM4: from bench (radiolabeling) to bedside (first-in-human study)

Sunday, June 12, 2022

Time (EDT)	Session and Title	Location	Abstract # and Title
12:30 p.m.-2:00 p.m.	SS10. Image Generation 1: Reconstruction and Quantitation	109	**2396.** Artifact free scatter correction of ^{68}Ga-RDG cervical cancer PET scans
3:00 p.m.-4:30 p.m.	SS15. Image Generation 2: Denoising & Motion	109	**2402.** Respiratory signal estimation and compensation using finely sampled projection data in pediatric ^{99m}Tc-labeled dimercaptosuccinic acid (DMSA) SPECT imaging: A simulation study
3:00 p.m.-4:30 p.m.	SS15. Image Generation 2: Denoising & Motion	109	**2403.** Quantification in Respiratory-Gated PET Acquisition: Can data-driven methods replace device-based systems?

Sunday, June 12, 2022 (continued)

Time (EDT)	Session and Title	Location	Abstract # and Title
3:00 p.m.-4:30 p.m.	SS15. Image Generation 2: Denoising & Motion	109	**2406.** Deep Learning for Inter-modal Image Registration with PET/CT
12:30 p.m.-2:00 p.m.	SS10. Image Generation 1: Reconstruction and Quantitation	109	**2395.** Evaluation of energy-based scatter compensation methods in clinical whole-body PET

Monday, June 13, 2022

Time (EDT)	Session and Title	Location	Abstract # and Title
10:00 p.m.-11:30 p.m.	SS17. Somatosatin Receptor imaging and PRRT	110	**2210.** Real-World Lesion and Renal Dosimetry for Peptide Receptor Radionuclide Therapy (PRRT)
10:00 p.m.-11:30 p.m.	SS17. Somatosatin Receptor imaging and PRRT	110	**2215.** Predicting ^{177}Lu-DOTATATE Kidney Dosimetry before Treatment from a Single ^{68}Ga-DOTATATE PET Scan and Clinical Biomarkers
1:00 p.m.-2:30 p.m.	SS21. Advances in atherosclerosis and inflammation imaging	116/117	**2219.** FAP-directed In-Vivo Molecular Imaging Identifies Increased Fibroblast Activation in Non-Calcified Plaque
1:00 p.m.-2:30 p.m.	SS21. Advances in atherosclerosis and inflammation imaging	116/117	**2220.** Coronary computed tomography angiography derived radiomic predictors of ^{18}F-sodium fluoride PET uptake
1:00 p.m.-2:30 p.m.	SS21. Advances in atherosclerosis and inflammation imaging	116/117	**2221.** Improved Quantification of Biologic Activity of Atherosclerosis Using Dynamic Whole-Body Positron Emission Tomography with Direct Patlak Reconstruction
10:00 a.m.-11:30 a.m.	Integrated Session 6. Advances in Tau imaging	205/206	**2225.** Head-to-head comparison of Relative Cerebral Blood Flow derived from dynamic ^{18}F-florbetapir and ^{18}F-flortaucipir PET studies in subjects with Subjective Cognitive Decline
10:00 a.m.-11:30 a.m.	Integrated Session 6. Advances in Tau imaging	205/206	**2226.** World Trade Center First Responders Exhibit Potentially Unique Tau Neuropathology: A Pilot PET/MRI Study
10:00 a.m.-11:30 a.m.	Integrated Session 6. Advances in Tau imaging	205/206	**2227.** Optimization of imaging time for ^{18}F-AV45 PET using SUVR in cognitive impairment with or without CAA by total-body dynamic PET/CT
10:00 a.m.-11:30 a.m.	SS18. Artificial Intelligence-Based Image Processing and Prediction	118/119/120	**2253.** Deep Transformer Based Direct Attenuation Correction of Myocardial Prefusion SPECT Images

Monday, June 13, 2022 (continued)

Time (EDT)	Session and Title	Location	Abstract # and Title
10:00 a.m.-11:30 a.m.	SS18. Artificial Intelligence-Based Image Processing and Prediction	118/119/120	**2255.** Forecasting the pharmacokinetics in dynamic brain PET imaging using Neural Ordinary Differential Equation: a step forward for dual-tracer studies
1:00 p.m.-2:30 p.m.	SS23. PSMA-targeted therapy	118/119/120	**2547.** Prostate-specific membrane antigen radioligand therapy using ^{177}Lu-PSMA I&T and ^{177}Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution and dosimetry
1:00 p.m.-2:30 p.m.	SS23. PSMA-targeted therapy	118/119/120	**2552.** Whole-body D50: a pragmatic quantitative SPECT-based dosimetric index for personalized PSMA radiopharmaceutical therapy with ^{177}Lu-PSMA-I&T
1:00 p.m.-2:30 p.m.	SS23. PSMA-targeted therapy	118/119/120	**2554.** Feasibility of single time point image-based dosimetry using prior knowledge: application to ^{177}Lu-PSMA-617 and ^{177}Lu-PSMA-I&T therapy of prostate cancer
10:00 a.m.-11:30 a.m.	SS16. Radiotherapy and Radiotheranostics	116/117	**2564.** FAP-targeted molecular radiotherapy synergizes with checkpoint inhibitor immunotherapy to attenuate tumor growth in a murine model of non-small cell lung cancer
10:00 a.m.-11:30 a.m.	SS16. Radiotherapy and Radiotheranostics	116/117	**2567.** Preclinical evaluation of a novel radioligand therapy for patients with prostate cancer: biodistribution and efficacy of ^{177}Lu-rhPSMA-10.1 in comparison with ^{177}Lu-PSMA-I&T
10:00 a.m.-11:30 a.m.	SS18. Artificial Intelligence-Based Image Processing and Prediction	118/119/120	**2252.** Generative adversarial network-based attenuation correction for ^{99m}Tc-TRODAT-1 brain SPECT
1:00 p.m.-2:30 p.m.	Integrated Session 7. Novel developments in prostate and liver imaging and therapy	205/206	**2477.** In the search of new chelator to improve prostate cancer radiotheranostic, the study of ^{64}Cu/^{177}Lu-CT-PCTA-PSMA
4:00 p.m.-5:30 p.m.	Integrated Session 8. Novel neuroreceptor radiotracers and brain/whole body applications	205/206	**2480.** An investigation of the "brain-GI" relationships in Parkinson's disease by imaging dopamine transporter in dynamic ^{11}C-CFT total-body PET/CT

Tuesday, June 14, 2022

Time (EDT)	Session and Title	Location	Abstract # and Title
1:00 p.m.-2:30 p.m.	Integrated Session 11. AI for Nuclear Medicine and Molecular Imaging	205/206	**2229.** Federated Learning on ^{18}F-FDG PET/CT Uptake Classification in Lung Cancer, Lymphoma and Head and Neck Cancer
1:00 p.m.-2:30 p.m.	Integrated Session 11. AI for Nuclear Medicine and Molecular Imaging	205/206	**2230.** Comparison of handcrafted radiomics and 3D-CNN models to diagnose striatal dopamine deficiency in Parkinson's Disease based on ^{18}F-FDOPA PET images
1:00 p.m.-2:30 p.m.	Integrated Session 11. AI for Nuclear Medicine and Molecular Imaging	205/206	**2232.** A Patlak-regularized deep learning inter-frame motion correction framework for whole-body dynamic PET
8:00 a.m.-9:30 a.m.	SS27. Applied & Novel Dosimetry in Clinical Applications	114/115	**2247.** Total-body perfusion imaging using ^{11}C-butanol
8:00 a.m.-9:30 a.m.	SS27. Applied & Novel Dosimetry in Clinical Applications	114/115	**2249.** Comparison of pre therapeutic and post therapeutic dosimetry with ^{177}Lu-Trastuzumab in patients with HER-2 positive metastatic breast cancer
8:00 a.m.-9:30 a.m.	SS26. Artificial Intelligence: Augmenting Cardiac Imaging	110	**2263.** Low-count Rb-82 cardiac PET/CT image denoising via deep learning for clinical dose reduction with preserved quantification accuracy
10:00 a.m.-11:30 a.m.	SS31. Basic Oncology: Early Phase Human Studies I	116/117	**2266.** ^{68}Ga-Pentixafor PET/CT for imaging CXCR4/CXCL12 receptor-ligand axis in lung cancer- A head –to- head comparison with ^{18}F-FDG PET/CT
10:00 a.m.-11:30 a.m.	SS31. Basic Oncology: Early Phase Human Studies I	116/117	**2269.** Peptide Targeted Radiotherapy using cancer-associated fibroblasts as target in solid tumors: first clinical experience with the ^{177}Lu-, ^{225}Ac- and ^{90}Y-labeled peptide 3BP-3940 (single isotope and TANDEM) targeting the Fibroblast Activating Protein
1:00 p.m.-2:30 p.m.	SS36. Basic Oncology: Early Phase Human Studies II	116/117	**2278.** Imaging of well-differentiated neuroendocrine tumors with the optimized SSTR antagonist ^{68}Ga-DATA5m LM4: first-in-human results
8:00 a.m.-9:30 a.m.	Integrated Session 9. Cardiac Amyloidosis: Advances in Imaging and clinical applications	205/206	**2293.** ^{99m}Tc-PYP SPECT/CT and ^{11}C-PIB PET/CT for cardiac involvement of transthyretin and light-chain amyloidosis
1:00 p.m.-2:30 p.m.	SS39. Gastrointestinal Malignancies	110	**2375.** Radioembolization for HCC Patients with Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D): an interim analysis
1:00 p.m.-2:30 p.m.	SS39. Gastrointestinal Malignancies	110	**2376.** Choice of Tyrosine Kinase Inhibitor (TKI) or Immune Check-point Inhibitor guided by dual-tracer (^{11}C-acetate and ^{18}F-FDG) PET/CT improves the progression-free survival in patients with advanced or metastatic HCC

Tuesday, June 14, 2022 (continued)

Time (EDT)	Session and Title	Location	Abstract # and Title
8:00 a.m.-9:30 a.m.	SS29. Pediatric nuclear medicine: FDG PET, total body PET and beyond	116/117	**2385.** Total-body PET/CT using half-dose ^{18}F-FDG in pediatric malignancies
8:00 a.m.-9:30 a.m.	SS29. Pediatric nuclear medicine: FDG PET, total body PET and beyond	116/117	**2392.** Role of ^{18}F-DOPA PET-CT in suspected congenital Hyperinsulinism
8:00 a.m.-9:30 a.m.	SS30. Image Segmentation, prognostic biomarkers	109	**2409.** Preliminary Evaluation of Lung Segment Parcellation for Lung Image Analysis
8:00 a.m.-9:30 a.m.	SS30. Image Segmentation, prognostic biomarkers	109	**2410.** ^{18}F-FDG-PET maximum intensity projections and artificial intelligence: a win-win combination to easily measure prognostic biomarkers in DLBCL patients
3:00 p.m.-4:30 p.m.	SS41. Kinetic modeling, quantification and dosimetry	114/115	**2431.** FDG-PET kinetic model identifiability and selection using machine learning
3:00 p.m.-4:30 p.m.	SS41. Kinetic modeling, quantification and dosimetry	114/115	**2435.** Triple time-point SPECT/CT to assess critical organ dosimetry in ^{177}Lu-DOTATATE radionuclide therapy for pediatric neuroblastoma: a relatively large cohort study
10:00 a.m.-11:30 a.m.	SS35. Novel tracers, therapies and applications in clinical oncology	109	**2493.** Assessment of the Prognostic value of PERCIST 1.0 and Simplified PERCIST ("SPERCIST")" FDG PET in Patients with Advanced Melanoma Treated with Immune Check-point Inhibitors
10:00 a.m.-11:30 a.m.	SS33. PSMA-targeted imaging	118/119/120	**2538.** PSMA PET mapping of postoperative local recurrence and impact on prostate fossa contouring guidelines for salvage radiation therapy
10:00 a.m.-11:30 a.m.	SS33. PSMA-targeted imaging	118/119/120	**2542.** Percutaneous transgluteal ^{68}Ga-PSMA PET/CT guided prostate biopsy: Is it the future?
10:00 a.m.-11:30 a.m.	SS33. PSMA-targeted imaging	118/119/120	**2544.** Optimal ^{68}Ga-PSMA PET/CT imaging in assessment of prostate cancer: feasibility of only delayed acquisition using a total-body PET/CT scanner?
3:00 p.m.-4:30 p.m.	SS44. CNS PET of neuroreceptors, vesicular transporters, synaptic vesicles and clinical applications	118/119/120	**2311.** Whole-body dynamic nicotine achetylcholinergic receptor PET imaging of abstaining smokers, a first in human study using the PennPET Explorer

Trademarks and service marks used in this material are property of Siemens Healthcare GmbH. All other company, brand, product and service names may be trademarks or registered trademarks of their respective holders.

Please contact your local Siemens Healthineers sales representative for the most current information or contact one of the addresses listed below. All photographs © 2022 Siemens Healthcare GmbH. All rights reserved.

"Siemens Healthineers" is considered a brand name. Its use is not intended to represent the legal entity to which this product is registered. Please contact your local Siemens organization for further details.

Siemens Healthineers Headquarters
Siemens Healthcare GmbH
Henkestr. 127
91052 Erlangen, Germany
Phone: +49 9131 84-0
siemens-healthineers.com

Published by
Siemens Medical Solutions USA, Inc.
Molecular Imaging
2501 North Barrington Road
Hoffman Estates, IL 60192
USA
Phone: +1 847 304-7700
siemens-healthineers.com/mi

MI-5622.RR.JV PDF only · © Siemens Healthcare GmbH, 06.2022